Search Results (1,166)

Severe dengue virus (DENV) infections are associated with circulating non-neutralizing antibodies generated during heterotypic infections. Although antibodies are key mediators of both protection and pathogenesis, the specific dynamics of B cells (Bc) and their antibody responses remain insufficiently characterized due to limited methods of identifying DENV-specific Bc (DENV-Bc) and the absence of animal models resembling the human disease. Here, we developed a spectral flow cytometry assay employing biotinylated virus-like particles (VLPs) to detect DENV-Bc in C57BL/6 mice and children hospitalized with dengue. DENV-1 and DENV-2 VLPs were biotinylated, and the efficiency of biotin incorporation was assessed with an HABA-avidin assay and ELISA. Serotype specificity and optimal binding conditions were confirmed using hybridomas 4G2 (pan-flavivirus) and 3H5-1 (DENV-2 specific). Fluorescent agglutimers were subsequently generated by coupling biotinylated VLPs to streptavidin–fluorochrome complexes. Splenocytes from intraperitoneally DENV-infected mice and peripheral blood mononuclear cells (PBMCs) from naturally infected pediatric patients were stained with these VLPs and Bc-lineage markers. Biotinylated VLPs bound specifically to hybridomas, and this binding was competitively inhibited by unlabeled VLPs. After secondary DENV challenge, VLPs identified DENV-specific class-switched plasmablasts in mice. Circulating DENV-specific plasmablasts were also detected in children, with agglutimers enabling the discrimination of serotype-specific and cross-reactive responses in primary and secondary infections. This VLP-based approach represents a scalable platform to investigate the protective and pathogenic roles of DENV-Bc in infection and vaccination. Full article

Dengue fever remains a major mosquito–borne disease worldwide, with over 400 million infections annually and a high risk of severe complications such as dengue hemorrhagic fever. The disease is prevalent in tropical and subtropical regions, where population density and limited vector control accelerate transmission, making early and reliable diagnosis essential for outbreak prevention and disease management. Conventional diagnostic methods, including virus isolation, reverse transcription polymerase chain reaction (RT–PCR), enzyme–linked immunosorbent assays (ELISA), and serological testing, are accurate but often constrained by high cost, labor–intensive procedures, centralized laboratory requirements, and delayed turnaround times. This review examines current dengue diagnostic technologies by outlining their working principles, performance characteristics, and practical limitations, with emphasis on key target analytes such as viral RNA; nonstructural protein 1 (NS1), including DENV–2 NS1; and host antibodies. Diagnostic approaches across commonly used biofluids, including whole blood, serum, plasma, and urine, are discussed. Recent advances in biosensing technologies are reviewed, including optical, electrochemical, microwave, microfluidic, and CRISPR–based platforms, along with the integration of artificial intelligence for data analysis and diagnostic enhancement. Overall, this review highlights the need for accurate, scalable, and field–deployable diagnostic solutions to support early dengue detection and reduce the global disease burden. Full article

Dengue (DENV), Chikungunya (CHIKV), and Zika (ZIKV) are emerging arboviral threats in Bangladesh, transmitted by Aedes mosquitoes thriving in urban Dhaka. Overlapping symptoms complicate diagnosis, and Bangladesh-specific data on arboviral antibody reactivity are limited. In four hospitals of Dhaka, we conducted a cross-sectional study on 438 febrile patients aged ≥10 years, collecting samples between September and December 2023 to describe arboviral antibody reactivity and their distribution across selected demographic and environmental characteristics. Rapid diagnostic tests (RDTs) for DENV and CHIKV were performed, followed by enzyme-linked immunosorbent assay (ELISA) on RDT-reactive samples. Participants had a mean age of 30 years (±13.5); two-thirds were male, and most lived in crowded, low-income households. RDTs indicated DENV/CHIKV antibody reactivity in 40% of participants; 170 samples underwent ELISA, suggesting DENV IgG reactivity in 33.5% and IgM reactivity in 15.5%. CHIKV IgG reactivity (0.7%) was low and ZIKV IgG was reactive in 21% of total samples, and IgM was reactive in one (0.2%); most ZIKV IgG-reactive samples also showed DENV IgG reactivity, suggesting cross-reactivity. DENV IgG and IgM reactivity were associated with lower education, while ZIKV IgM reactivity was associated with older age. Awareness of Aedes mosquitoes was low, and environmental risk factors were common. This study provides cross-sectional data on serological reactivity against DENV, CHIKV, and ZIKV among febrile patients attending four hospitals of Dhaka, without aiming to establish etiologic causes of illness. ZIKV IgG antibody reactivity requires confirmatory testing to distinguish true infections from other arboviral cross-reactivity. Strengthened community-based surveys, better public awareness, and sustained vector control are critical for reducing arboviral disease risks in urbanizing settings like Dhaka, Bangladesh. Full article

Background: In this study, we report a novel series of proline- and pipecolic acid-based small molecules designed as allosteric inhibitors of the NS2B/NS3 serine proteases from dengue and Zika viruses, key targets in antiviral drug discovery. Results: Enzymatic studies revealed that S-proline derivatives bearing electron-withdrawing substituents on the aromatic ring, particularly that with a trifluoromethyl group in meta position (i.e., compound 3, IC₅₀ = 5.0 µM), were the most potent against DENV NS2B/NS3, while nitro-substituted inhibitors were mostly effective only against the ZIKV protease. R-configured pipecolic acid-based derivatives were the only ones active against DENV NS2B/NS3, even if the mid-micromolar range; however, they demonstrated improved cellular efficacy since inhibitors 24 and 27 exhibiting strong activity in a DENV2 protease reporter gene assay (EC₅₀ = 5.2 and 5.1 µM, respectively). All compounds showed no cytotoxicity (CC₅₀ > 100 µM) and were selective for the viral protease over off-target serine proteases. Structure-based approaches were exploited to map the druggable allosteric site close to Asn152. Conclusions: Our findings led us to identify proline and pipecolic acid-based inhibitors as promising leads for the development of selective flaviviral NS2B/NS3 allosteric inhibitors. Full article

Background: Being central players in the adaptive immunity, the study of T-cell responses is crucial in both natural infections and vaccine-induced immunity. In this study, we assessed the antigen-specific T-cell responses to dengue virus (DENV) to identify the most immunogenic antigen for evaluating dengue-specific T-cell responses. Methods: Patients with dengue disease and subjects vaccinated with the QDENGA (TAK-003) vaccine (before and three months after vaccination) were enrolled. The T-cell-specific response was measured by ELISPOT and Activation Induced Markers (AIM) assay following PBMC stimulation either with DENV1-4 CD4 and CD8 MegaPools (MP) or serotype-specific DENV peptide pools at different concentrations. Results: We found that both DENV1-4 CD4 MP (at 1 µg/mL) and CD8 MP (at 5 µg/mL), which encompass all four DENV serotypes, elicited specific T-cell responses in patients with dengue infection independent of the infecting serotype. In contrast, selected serotype-specific DENV peptide pools have a lower ability to induce a measurable T-cell response. Moreover, DENV1-4 CD4 and CD8 MPs, at the highest concentrations, are suitable candidates to evaluate the dengue-specific T-cell response in vaccinated subjects. Conclusions: These findings support the use of the MP approach to investigate dengue-specific T-cell response to monitor the response during the infection and after vaccine administration. Full article

The year 2025 likely marks a turning point in both the perception and the reality of mosquito-borne arboviral diseases in Europe. While chikungunya and dengue viruses have long been regarded as tropical illnesses confined to intertropical regions, West Nile virus has circulated for decades in temperate areas, including southern Europe. Nevertheless, all three mosquito-borne viruses are now increasingly established across the European continent. This evolution reflects a profound transformation of the European epidemiological landscape, where arboviral diseases are increasingly emerging as endemic and seasonal threats. This shift concerns not only the scale but also the dynamics of transmission, with the appearance of newly affected regions, an earlier onset of the transmission season, and a broader diversity of arboviruses involved. Europe is thus entering a new phase in which longer, wider, and more intense transmission of vector-borne diseases is likely to become the new norm requiring strengthened preparedness. Full article

Background/Objectives: Colombia harbors exceptional plant diversity, comprising over 31,000 formally identified species, of which approximately 6000 are classified as useful plants. Among these, 2567 species possess documented food and medicinal applications, with several traditionally utilized for managing febrile illnesses. Despite the global burden of dengue virus infection affecting millions annually, no specific antiviral therapy has been established. This study aimed to identify potential anti-dengue compounds from Colombian medicinal flora through machine learning-based quantitative structure–activity relationship (QSAR) modeling. Methods: An optimized XGBoost algorithm was developed through Bayesian hyperparameter optimization (Optuna, 50 trials) and trained on 2034 ChEMBL-derived activity records with experimentally validated anti-dengue activity (IC₅₀/EC₅₀). The model incorporated 887 molecular features comprising 43 physicochemical descriptors and 844 ECFP4 fingerprint bits selected via variance-based filtering. IC₅₀ and EC₅₀ endpoints were modeled independently based on their pharmacological distinction and negligible correlation (r = −0.04, p = 0.77). Through a systematic literature review, 2567 Colombian plant species from the Humboldt Institute’s official checklist were evaluated (2501 after removing duplicates and infraspecific taxa), identifying 358 with documented antiviral properties. Phytochemical analysis of 184 characterized species yielded 3267 unique compounds for virtual screening. A dual-endpoint classification strategy categorized compounds into nine activity classes based on combined potency thresholds (Low: pActivity ≤ 5.0, Medium: 5.0 < pActivity ≤ 6.0, High: pActivity > 6.0). Results: The optimized model achieved robust performance (Matthews correlation coefficient: 0.583; ROC-AUC: 0.896), validated through hold-out testing (MCC: 0.576) and Y-randomization (p < 0.01). Virtual screening identified 276 compounds (8.4%) with high predicted potency for both endpoints (“High-High”). Structural novelty analysis revealed that all 276 compounds exhibited Tanimoto similarity < 0.5 to the training set (median: 0.214), representing 145 unique Murcko scaffolds of which 144 (99.3%) were absent from the training data. Application of drug-likeness filtering (QED ≥ 0.5) and applicability domain assessment identified 15 priority candidates. In silico ADMET profiling revealed favorable pharmaceutical properties, with Incartine (pIC₅₀: 6.84, pEC₅₀: 6.13, QED: 0.83), Bilobalide (pIC₅₀: 6.78, pEC₅₀: 6.07, QED: 0.56), and Indican (pIC₅₀: 6.73, pEC₅₀: 6.11, QED: 0.51) exhibiting the highest predicted potencies. Conclusions: This systematic computational screening of Colombian medicinal flora demonstrates the untapped potential of regional biodiversity for anti-dengue drug discovery. The identified candidates, representing structurally novel chemotypes, are prioritized for experimental validation. Full article

Dengue Virus (DENV) induces assembly of the NOD-like receptor (NLR) family pyrin domain containing-3 (NLRP3) inflammasome and autophagy, which are closely interconnected processes playing crucial roles in lipid metabolism and DENV replication. However, the autophagy–NLRP3 activation interplay during DENV infection in human endothelial cells remains incompletely understood. We aimed to elucidate effects of NLRP3 activation on autophagy during DENV-2 infection. We investigated how autophagy-related molecules are altered by NLRP3 inhibition and how this regulation affects lipid metabolism, through the master lipid transcription factors SREBP-1 and 2, which increase the expression of their target lipid-synthesizing genes such as fatty acid synthase (FAS) in a model of microvascular endothelial cells (HMEC-1). We demonstrated a dynamic interplay between inflammasome activity and autophagy in DENV-infected HMEC-1 cells: autophagy increases early during infection and decreases as inflammasome activity increases. NLRP3 inflammasome inhibition affects viral replication. Glyburide (an inflammasome inhibitor) treatment partially inhibited DENV-induced NLRP3 inflammasome activation. Non-structural viral protein expression (NS3 and NS5) and infectious viral-particle formation were significantly reduced. NLRP3 inhibition also downregulated SREBP-1 and SREBP-2 activation. These findings provide new insights into the modulation of the interconnected NLRP3 inflammasome, autophagy, and lipid metabolism pathways, presenting a promising therapeutic strategy for severe clinical forms of dengue. Full article

This study evaluated hepatic pathological and phenotypic alterations, along with the inflammatory response, following sequential dengue virus (DENV) infection in Callithrix penicillata, a relevant model for human endemic scenarios. Twenty-six animals were initially infected subcutaneously with DENV-3. Thirteen were euthanized between 1 and 7 days post-infection (dpi) to assess the acute phase, and up to 60 dpi for the convalescent phase. The remaining animals received a secondary DENV-2 infection two months later. Liver samples underwent histopathological and immunohistochemical analysis. Viral antigens were identified in hepatocytes, Kupffer cells, and Councilman bodies. Observed liver changes included apoptosis, lytic necrosis, midzonal inflammation, Kupffer cell hyperplasia and hypertrophy, sinusoidal dilation, and hemosiderin deposition. Both primary and secondary infections increased activated macrophages, NK cells, S-100 protein, and B lymphocytes. Primary infection was associated with elevated CD4⁺ T cells, IFN-γ, TGF-β, IL-10, and Fas expression, whereas secondary infection induced higher IFN-γ, TNF-α, IL-8, Fas, and VCAM levels. These findings mirror hepatic alterations in severe human dengue cases and underscore the role of direct viral effects and immune dysregulation in liver injury. The results support C. penicillata as a suitable non-human primate model for studying DENV pathogenesis. Full article

Oropouche virus (OROV) is an emerging and underreported arbovirus with dengue-like symptoms confounding diagnosis. OROV is also neuroinvasive, with a small number of cases presenting severe neurological symptoms. There have been recently reported deaths from confirmed cases of OROV and reported instances of vertical transmission from mother to foetus, with confirmed cases in Brazil and a congenital anomaly, reportedly as a consequence of OROV infection in Cuba, with further cases under investigation. Whilst cases of OROV infection occur mainly in South America, many cases have been imported elsewhere, including the United States and Europe. Despite the emerging threat to public health, animal modelling to study OROV pathogenicity and immunity and to evaluate therapeutic candidates remains limited. For this review, we carried out a literature search through major research databases (PubMed and Scopus) up to September 2025 to capture the extent of in vivo model development for this pathogen. We identified only 17 relevant primary research articles within these criteria which detailed hamster, mouse and non-human primate (NHP) models. Here, we discuss the extent of in vivo model development for OROV. In summary, small and large animal models need to be assessed with recent clinical isolates and reassortants, asymptomatic disease presentation in the NHP model requires further study and the hamster model shows potential for use in pathogenicity and vaccine or antiviral efficacy studies. We also compile relevant metadata and discuss the need for an animal model that more closely resembles human disease. Full article

Apart from some information on dengue virus (DENV), there is limited data on the circulation of arboviruses in Burkina Faso. The aim of this study was to investigate antibody prevalence against six arboviruses in four regions of the country to document previous virus exposure. Serum samples collected between August 2018 and December 2022 from people infected with viral hepatitis B and C in Bobo-Dioulasso were used to detect IgG antibodies against DENV, Chikungunya virus (CHIKV), Zika virus (ZIKV), Yellow fever virus (YFV), Rift Valley fever virus (RVFV) and Crimean-Congo hemorrhagic fever virus (CCHFV) using commercial ELISA kits. A total of 1808 serum samples, accompanied by basic epidemiologic data (sex, age and residency) were included in this study. We observed an IgG antibodies seroprevalence of 75.4% for DENV, 30.8% for CHIKV, 2.9% for ZIKV, 1.2% for RVFV, 1.1% for CCHFV and 1.1% for YFV. Age, sex, and place of residence were significantly associated with seropositivity for DENV and age and sex with CHIKV seropositivity. The results suggested widespread circulation of DENV and CHIKV and possible circulation of CCHFV and RVFV in humans in Burkina Faso. The importance of strengthening arbovirus surveillance by including additional arboviruses in the diagnostic panel is emphasized. Full article

Protein–protein interactions (PPIs) are fundamental to viral replication, regulating transcription, assembly, and genome packaging. Despite their biological importance, few FDA-approved therapeutics directly target these complexes. The split luciferase complementation assay (SLCA) is a quantitative bioluminescence system to measure protein–protein interactions in vitro after the proteins in question have been fused in-frame to N and C luciferase fragments. The SLCA can be performed both in vitro using purified protein components and in live cells, as the luciferase substrate luciferin is cell-permeable, allowing detection of protein interactions in intact cells. Assay performance, however, depends on the expression level and stability of the fusion proteins used. SLCA has been successfully applied to target Rev–Rev interactions in human immunodeficiency virus type 1 (HIV-1) for high-throughput small-molecule screening, establishing a proof-of-concept to target other parts of the viral life cycle. The system can be extended to other pathogens that currently do not have specific antiviral therapies such as HIV-1 Tat–cyclin T1, Capsid dimerization in Dengue virus, capsid interactions in equine encephalitis viruses, capsid assembly in Epstein–Barr virus, and nucleoprotein oligomerization in rabies virus. These applications demonstrate how the assay’s ability to quantify multimeric structural interactions is essential to viral replication, providing an avenue to identify small-molecule inhibitors that prevent viral replication and spread. Although there are challenges to protein stability and assay optimization, the sensitivity and adaptability of the SLCA has broader implications in virology to accelerate antiviral drug development. Full article

The four serotypes of dengue virus (DENV), types 1 to 4 (DENV-1 to DENV-4), exhibit approximately 60% identity in the encoded amino acid residues of viral proteins. Reverse transcription of RNA extracted from patient serum specimens followed by PCR amplification with serotype-specific probes is the current standard technique for DENV serotyping. However, this method is time- and cost-consuming, and rapid detection systems with low cost are desirable. Previously, we developed a prototype serotype-specific immunochromatography system. That system was composed of four strips with four corresponding distinct sample buffers, each specifically detecting a single DENV serotype. In the present study, we improved this system by combining pairs of strips into one lateral-flow cassette each, providing DENV-1 and DENV-2 detection in one device and DENV-3 and DENV-4 detection in a second device; this strategy successfully reduced the required sample volume. Furthermore, we were able to adjust the composition of the sample buffers such that a single sample buffer sufficed for all four DENV serotype detection reactions, allowing much easier handling of the devices. Evaluation of this new device against laboratory and clinical DENV isolates and clinical specimens from DENV-infected individuals showed sensitivity that was comparable to that of our previous version, yielding serotype specificity of 100%. These new devices are expected to be of use in the clinical setting, accelerating both prospective and retrospective epidemiological studies. Full article

Dengue virus (DENV) and Zika virus (ZIKV) are flaviviruses transmitted by Aedes spp. mosquitoes, causing a spectrum of symptoms ranging from mild fevers and joint pain to severe damage to vital organs, including the kidneys, brain, and liver. Unfortunately, there are currently no specific treatments for these viruses. The NS2B/NS3 serine protease has been recognized as a crucial therapeutic target due to its pivotal role in viral replication. Herein, several molecular modeling techniques were employed to search for novel allosteric inhibitors against DENV and ZIKV NS2B/NS3 proteases from a set of 545 in-house compounds. Virtual screening based on molecular docking and MM/GBSA-based free energy calculations indicated that, among 545 derivatives, four compounds demonstrated high binding affinity against both targets, including two sulfonamide-vinyl sulfone hybrids (cpd48_e and cpd50_e), one sulfonamide-chalcone analog (cpd48), and one berberine-cinnamic acid derivative (DN071_f). Their molecular complexation was driven mainly by van der Waals forces rather than electrostatic attraction. Several residues at the enzyme allosteric site, particularly K74, L149, and N152 (DENV) and L76, I123, N152, and V155 (ZIKV), were identified as binding hotspots for the screened compounds. Drug-likeness predictions based on Lipinski’s rule of five further supported their potential as drug candidates. Overall, these findings provide valuable insights for the future design and development of novel antiviral drugs targeting the DENV and ZIKV NS2B/NS3 proteases. Full article

Dengue fever has become a major global public health challenge due to its rapidly in-creasing incidence. Rapid on-site detection of dengue virus (DENV) is critical for early diagnosis, timely patient isolation, and outbreak control. In this study, dengue virus serotype 2 (DENV-2), the predominant strain circulating in tropical and subtropical regions, was selected as the target pathogen. We established a one-tube rapid detection assay that integrates the HUDSON nucleic acid extraction-free protocol, reverse transcription recombinase-aided amplification (RT-RAA), and CRISPR/Cas12a-mediated trans cleavage activity. The method achieved a detection limit of 1 × 10² copies/μL for simulated infected samples and exhibited no cross-reactivity with other DENV serotypes (DENV-1, DENV-3, DENV-4) or with other arboviruses, including Zika, Japanese encephalitis, yellow fever, and chikungunya viruses. The assay demonstrated high sensitivity and specificity across various sample types, including mosquitoes, rodents, blood, and cultured cells, with results consistent with quantitative PCR (qPCR). Requiring only basic equipment such as a water bath, the system enables on-site detection of DENV-2 within 1 h. This simple, cost-effective, and reliable assay provides a practical tool for field-based DENV-2 surveillance and supports effective public health responses in resource-limited settings. Full article